PTPN1 is a negative regulator of the insulin-PI3K/Akt signaling pathway [45] and is considered a potential therapeutic target for metabolic syndrome, obesity, and diabetes [46]. Here, AKT1 is linked to obesity due to melanocortin 4 receptor deficiency.